Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Deals

Ouro Medicines Launches with $120M Series A Financing for CM336 Development

Fineline Cube Jan 13, 2025

Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched...

Company Deals

Menarini Group Expands Oncology Pipeline with Insilico Medicine License

Fineline Cube Jan 13, 2025

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...

Company Deals

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Fineline Cube Jan 13, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced an exclusive collaboration and...

Company Deals

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Fineline Cube Jan 13, 2025

US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...

Company Deals

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development

Fineline Cube Jan 13, 2025

US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...

Company Deals

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Fineline Cube Jan 13, 2025

South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...

Company Deals

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices

Fineline Cube Jan 13, 2025

Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...

Company Drug

Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech

Fineline Cube Jan 13, 2025

Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...

Company Drug

Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study

Fineline Cube Jan 13, 2025

US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...

Company Drug

NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma

Fineline Cube Jan 13, 2025

China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...

Company Drug

Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech

Fineline Cube Jan 13, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...

Company Drug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

Fineline Cube Jan 13, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...

Policy / Regulatory

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...

Policy / Regulatory

China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...

Company

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding

Fineline Cube Jan 11, 2025

Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...

Company Drug

Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment

Fineline Cube Jan 11, 2025

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...

Company Drug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment

Fineline Cube Jan 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...

Company Deals

Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development

Fineline Cube Jan 11, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...

Company Deals

Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109

Fineline Cube Jan 11, 2025

China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...

Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Posts pagination

1 … 210 211 212 … 647

Recent updates

  • Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission
  • Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions
  • Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests
  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Others

Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.